

Cdk2/Cyclin Inhibitory Peptide I

Cat. No.:	HY-P3730
CAS No.:	237392-84-6
Molecular Formula:	C ₁₁₁ H ₁₉₆ N ₄₈ O ₂₃
Molecular Weight:	2571.05
Sequence Shortening:	YGRKKRRQRRRGPVKRRFLFG
Target:	CDK
Pathway:	Cell Cycle/DNA Damage
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.

BIOLOGICAL ACTIVITY

Description	Cdk2/Cyclin Inhibitory Peptide I (Tat-LFG), a CDK2 inhibitor, kills U2OS osteosarcoma cells in a dose-dependent manner ^[1] .	
IC₅₀ & Target	CDK2 ^[1] .	
In Vitro	Cdk2/Cyclin Inhibitory Peptide I (0-150 μM; 24 h) kills U2OS osteosarcoma cells in a dose-dependent manner ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only. Cell Viability Assay ^[1]	
	Cell Line:	U2OS osteosarcoma cells
	Concentration:	0-150 μM
	Incubation Time:	24 h
	Result:	Exhibited good activity to kill U2OS osteosarcoma cells.

REFERENCES

[1]. Chen YN, et al. Selective killing of transformed cells by cyclin/cyclin-dependent kinase 2 antagonists. Proc Natl Acad Sci U S A. 1999 Apr 13;96(8):4325-9.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA